Sunflower Pharmaceutical Group Co.,Ltd

Shenzhen Stock Exchange 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd Free Cash Flow for the year ending December 31, 2023: USD 104.30 M

Sunflower Pharmaceutical Group Co.,Ltd Free Cash Flow is USD 104.30 M for the year ending December 31, 2023, a -60.41% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Sunflower Pharmaceutical Group Co.,Ltd Free Cash Flow for the year ending December 31, 2022 was USD 263.43 M, a 124.10% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Free Cash Flow for the year ending December 31, 2021 was USD 117.55 M, a -19.83% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Free Cash Flow for the year ending December 31, 2020 was USD 146.63 M, a 68.20% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Free Cash Flow for the year ending December 31, 2019 was USD 87.18 M, a 9.95% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shenzhen Stock Exchange: 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd

CEO	Ms. Yi Guan
IPO Date	Dec. 30, 2014
Location	China
Headquarters	Concentrated Area, Yingbin Road
Employees	5,776
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sunflower Pharmaceutical Group Co.,Ltd researches, develops, manufactures, and markets Chinese patent medicines in China. The company also produces chemical, biological, and health care medicines. Its products are used in therapeutic areas, such as pediatrics, gynecology, digestive system, respiratory and cold, rheumatism and bone disease, and cardiovascular and cerebrovascular. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is based in Harbin, China.

Key trends

Past 5 years